Category: Clinical Data
PharmaSignal — Clinical Data
Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study
Pharmaceutical Technology
Boehringer Ingelheim and Zai Lab have entered into a clinical collaboration to investigate a dual DLL3-targeting approach for patients with ES-SCLC and other NECs.
Revolution rockets on strong pancreatic cancer data
Pharmaphorum
Revolution Medicines thinks it could transform the treatment of pancreatic cancer based on phase 3 data with its pan-RAS(on) inhibitor daraxonrasib.
Spyre drug for inflammatory bowel disease shows promise in early study
BioPharma Dive
The therapy, which works similarly to Takeda s blockbuster Entyvio, showed remission rates that suggest a best-in-class profile, the company said.
Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma
BioPharma Dive
Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a donor-derived cell therapy.
Allogene stock sails after CAR T clears residual lymphoma in early data cut
BioSpace
Pivotal findings for the off-the-shelf cell therapy surpassed William Blair’s expectations and sent Allogene Therapeutics’ stock up more than 50% in pre-market trading Monday morning.
Revolution rises 40% as pancreatic cancer drug doubles survival
BioSpace
In a difficult disease, Revolution Medicines achieved what the pancreatic cancer community has long desired: a significant improvement in survival.
IDEAYA/Servier PKC drug aces uveal melanoma trial
Pharmaphorum
Servier $210m bet on IDEAYA’s uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026.
Data backs GSK’s ovarian cancer blockbuster hopes
Pharmaphorum
GSK’s B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme.
Kainova expands DT 7012 trial into Europe
PharmaTimes
First patient dosed as DOMISOL study grows beyond Australia
23andMe study explains variable results with obesity drugs
Pharmaphorum
Gene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects.
Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
PharmaTimes
Subcutaneous delivery shows IVlevel efficacy in moderate to severe TED
CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
PharmaTimes
Study expands development of the antibody into hepatocellular carcinoma
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
BioSpace
Sanofi has faced questions about the potential of lunsekimig in eczema, with executives calling the clinical trial a “measured risk.”
Sanofi immune drug hopeful posts mixed results in mid-stage tests
BioPharma Dive
Lunsekimig, a bispecific drug aimed at two popular targets, succeeded in studies in asthma and nasal polyps but missed its mark in an eczema trial.
Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3
BioSpace
Sales of Amgen’s thyroid eye disease drug Tepezza have slowed, dipping 1% to $457 million in the fourth quarter of 2025.
Amgen scores with new thyroid eye disease formulation
Pharmaphorum
Can Amgen’s subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster?
ACC 2026: sotatercept meta-analysis backs disease-modifying role in PAH
Pharmaceutical Technology
New data presented at ACC 2026 clarifies sotatercept’s role alongside vasodilator-based regimens in PAH patients.
Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment
BioSpace
COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver relevant post-marketing data.
AZ claims another win for Imfinzi in frontline liver cancer
Pharmaphorum
AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme.